查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球臨床試驗用品市場：市場規模、市場份額、趨勢分析、機遇和預測：按產品、臨床階段、治療用途、最終用途、地區劃分 (2019-2029)
市場調查報告書
商品編碼
1217686

全球臨床試驗用品市場：市場規模、市場份額、趨勢分析、機遇和預測：按產品、臨床階段、治療用途、最終用途、地區劃分 (2019-2029)

Clinical Trial Supplies Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Clinical Phase ; By Therapeutic Use ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 270 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球臨床試驗用品市場規模將從2022年的20億美元增長到2029年的29億美元，在2023年至2029年的預測期內（2022-2028）佔5.09%，預計複合年增長率為 各種慢性病和流行病的流行率上升，製藥公司、政府和研究機構對臨床試驗的大量投資正在推動市場的增長。

本報告考察了全球臨床試驗用品市場，並提供了全面的信息，包括市場概況、市場分析和公司概況。

內容

第一章研究框架

第 2 章執行摘要

第 3 章全球臨床試驗用品市場洞察

  • 行業價值鏈分析
    • DROC 分析
    • 司機
      • 藥物和生物製藥的研發費用增加
      • 慢性病和傳染病的負擔不斷增加
    • 約束因素
      • 藥物不良反應
    • 機會
      • 新興國家新藥開發試驗的出現
    • 任務
      • COVID-19 對供應鏈的影響
  • 技術進步/最新發展
  • 監管框架
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭激烈程度

第 4 章全球臨床試驗用品市場概述

  • 市場規模和預測（2019-2029 年）
    • 按金額（百萬美元）
  • 市場份額和預測
    • 按產品分類
      • 製造業
      • 供應鏈管理
      • 物流
      • 存儲和分發
      • 其他
    • 按臨床分期
      • 第一階段
      • 第二階段
      • 第三階段
      • 其他
    • 通過治療用途
      • 腫瘤
      • 中樞神經系統
      • 心血管
      • 感染
      • 代謝紊亂
      • 其他
    • 按最終用途
      • 醫藥
      • 生物製劑
      • 醫療設備
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第五章北美臨床試驗用品市場

第 6 章歐洲臨床試驗用品市場

第七章亞太臨床試驗用品市場

第 8 章拉丁美洲臨床試驗用品市場

第9章中東和非洲臨床試驗用品市場

第10章競爭格局

  • 主要公司及其產品列表
  • 全球臨床試驗供應公司的市場份額分析（2022 年）
  • 競爭基準：按操作參數
  • 重大戰略發展（合併、收購、合作等）

第 11 章 COVID-19 對全球臨床試驗用品市場的影響

第12章公司概況（公司概況、財務矩陣、競爭格局、關鍵人才、主要競爭對手、聯繫人、戰略展望、SWOT分析）

  • Alamc Group
  • Catalent, Inc.
  • PCI Services
  • Parexel International Corporation
  • Sharp Packaging Services
  • Biocair
  • O&M Movianto
  • KLIFO A/S
  • Thermo Fisher Scientific, Inc.
  • Movianto
  • Sharp
  • Catalent, Inc
  • Bionical Ltd.
  • Alium Medical Limited
  • 其他

第 13 章關鍵戰略建議

第 14 章研究方法論

簡介目錄
Product Code: BWC20102

Global Clinical Trial Supplies Market Size Booming to Touch USD 3 Billion by 2029

Global clinical trial supplies market is gaining traction because of an increasing focus on R&D innovative medicines to treat growing prevalence of various chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global clinical trial supplies market size at USD 2 billion in 2022. During the forecast period between 2023 and 2029, the global clinical trial supplies market size is projected to grow at a steady CAGR of 5.09% reaching a value of USD 2.9 billion by 2029. The increased prevalence of different chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions are key growth drivers for the global clinical trial supplies market. The global clinical trial supplies market is expected to grow during the forecast period as a result of the pharmaceutical and biotechnology firms' increasing investments in research and development activities for medication development.

Global Clinical Trial Supplies Market - Overview:

Clinical trials are research projects conducted on human subjects to assess a therapeutic, surgical, or behavioral intervention. Clinical trials often fall into one of three categories: Interventional studies seek to learn more about a specific intervention or kind of treatment. Observational studies seek to understand how individuals behave in various contexts. Feasibility studies are intended to determine whether the primary research can be conducted. The provision of materials needed to execute a clinical trial is known as clinical supply or clinical trial supply. This includes the 24-hour collection and distribution of biological specimens (including infectious samples), experimental medications, kits, and other research materials and supplies, as well as knowledge and help.

Global Clinical Trial Supplies Market - By End Use:

Based on end use, the global clinical trial supplies market is segmented into pharmaceuticals, biologics, medical devices, and others. Pharmaceutical companies account for the highest market share owing to the increasing number of clinical trials for drug development. Pharmaceutical companies use clinical trial supplies for collection and delivery of biological specimens, investigational drugs, and others. However, the biologics segment is expected to gain high traction during the forecast period owing to extensive research activities around the development of drugs from biologics such as blood, proteins, viruses, or living organisms.

Impact of COVID-19 on the Global Clinical Trial Supplies Market

COVID-19 elevated the critical nature of clinical trial supplies and their importance to the healthcare market. Although the global clinical trial supplies market was initially hindered during the pandemic period as the imposition of lockdowns in various countries halted the clinical trials of various therapeutic purposes, which significantly impacted the market growth. To complete vaccine development activities after the pandemic outbreak and stop any further human deaths, clinical trial sponsors, their clinical research organizations, study teams, and other important stakeholders, such as vendors, had to work cooperatively to secure clinical trial supplies.

Competitive Landscape:

Major players operating in the global Clinical Trial Supplies market include Almac Group, Catalent, Inc., PCI Services, Parexel International Corporation, Sharp Packaging Services, Biocair, O&M Movianto, KLIFO A/S, Thermo Fisher Scientific, Inc., Movianto, Sharp, Catalent, Inc, Bionical Ltd., and Alium Medical Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Clinical Trial Supplies Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Clinical Trial Supplies Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Clinical Trial Supplies Market Insights

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. DROC Analysis
    • 3.1.2. Growth Drivers
      • 3.1.2.1. Increasing Pharmaceutical and Biopharmaceutical R&D Expenditures
      • 3.1.2.2. Rising Burden of Chronic and Communicable Diseases
    • 3.1.3. Restraints
      • 3.1.3.1. Adverse Drug Reactions
    • 3.1.4. Opportunities
      • 3.1.4.1. Rising New Drug Development Trial in Emerging Countries
    • 3.1.5. Challenges
      • 3.1.5.1. Impact of COVID-19 on Supply Chain
  • 3.2. Technology Advancements/Recent Developments
  • 3.3. Regulatory Framework
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry

4. Global Clinical Trial Supplies Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Manufacturing
      • 4.2.1.2. Supply Chain Management
      • 4.2.1.3. Logistics
      • 4.2.1.4. Storage & Distribution
      • 4.2.1.5. Others
    • 4.2.2. By Clinical Phase
      • 4.2.2.1. Phase I
      • 4.2.2.2. Phase II
      • 4.2.2.3. Phase III
      • 4.2.2.4. Others
    • 4.2.3. By Therapeutic use
      • 4.2.3.1. Oncology
      • 4.2.3.2. CNS
      • 4.2.3.3. Cardiovascular
      • 4.2.3.4. Infectious Disease
      • 4.2.3.5. Metabolic Disorders
      • 4.2.3.6. Others
    • 4.2.4. By End Use
      • 4.2.4.1. Pharmaceutical
      • 4.2.4.2. Biologics
      • 4.2.4.3. Medical Device
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Clinical Trial Supplies Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Clinical Phase
    • 5.2.3. By Therapeutic use
    • 5.2.4. By End Use
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Product
      • 5.2.5.1.2. By Clinical Phase
      • 5.2.5.1.3. By Therapeutic use
      • 5.2.5.1.4. By End Use
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product
      • 5.2.5.2.2. By Clinical Phase
      • 5.2.5.2.3. By Therapeutic use
      • 5.2.5.2.4. By End Use

6. Europe Clinical Trial Supplies Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Clinical Phase
    • 6.2.3. By Therapeutic use
    • 6.2.4. By End Use
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product
      • 6.2.5.1.2. By Clinical Phase
      • 6.2.5.1.3. By Therapeutic use
      • 6.2.5.1.4. By End Use
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Product
      • 6.2.5.2.2. By Clinical Phase
      • 6.2.5.2.3. By Therapeutic use
      • 6.2.5.2.4. By End Use
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product
      • 6.2.5.3.2. By Clinical Phase
      • 6.2.5.3.3. By Therapeutic use
      • 6.2.5.3.4. By End Use
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product
      • 6.2.5.4.2. By Clinical Phase
      • 6.2.5.4.3. By Therapeutic use
      • 6.2.5.4.4. By End Use
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product
      • 6.2.5.5.2. By Clinical Phase
      • 6.2.5.5.3. By Therapeutic use
      • 6.2.5.5.4. By End Use
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Product
      • 6.2.5.6.2. By Clinical Phase
      • 6.2.5.6.3. By Therapeutic use
      • 6.2.5.6.4. By End Use
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Product
      • 6.2.5.7.2. By Clinical Phase
      • 6.2.5.7.3. By Therapeutic use
      • 6.2.5.7.4. By End Use

7. Asia-Pacific Clinical Trial Supplies Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Clinical Phase
    • 7.2.3. By Therapeutic use
    • 7.2.4. By End Use
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product
      • 7.2.5.1.2. By Clinical Phase
      • 7.2.5.1.3. By Therapeutic use
      • 7.2.5.1.4. By End Use
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product
      • 7.2.5.2.2. By Clinical Phase
      • 7.2.5.2.3. By Therapeutic use
      • 7.2.5.2.4. By End Use
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product
      • 7.2.5.3.2. By Clinical Phase
      • 7.2.5.3.3. By Therapeutic use
      • 7.2.5.3.4. By End Use
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product
      • 7.2.5.4.2. By Clinical Phase
      • 7.2.5.4.3. By Therapeutic use
      • 7.2.5.4.4. By End Use
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product
      • 7.2.5.5.2. By Clinical Phase
      • 7.2.5.5.3. By Therapeutic use
      • 7.2.5.5.4. By End Use
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product
      • 7.2.5.6.2. By Clinical Phase
      • 7.2.5.6.3. By Therapeutic use
      • 7.2.5.6.4. By End Use
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product
      • 7.2.5.7.2. By Clinical Phase
      • 7.2.5.7.3. By Therapeutic use
      • 7.2.5.7.4. By End Use
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product
      • 7.2.5.8.2. By Clinical Phase
      • 7.2.5.8.3. By Therapeutic use
      • 7.2.5.8.4. By End Use
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Product
      • 7.2.5.9.2. By Clinical Phase
      • 7.2.5.9.3. By Therapeutic use
      • 7.2.5.9.4. By End Use
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Product
      • 7.2.5.10.2. By Clinical Phase
      • 7.2.5.10.3. By Therapeutic use
      • 7.2.5.10.4. By End Use
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Product
      • 7.2.5.11.2. By Clinical Phase
      • 7.2.5.11.3. By Therapeutic use
      • 7.2.5.11.4. By End Use

8. Latin America Clinical Trial Supplies Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Clinical Phase
    • 8.2.3. By Therapeutic use
    • 8.2.4. By End Use
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product
      • 8.2.5.1.2. By Clinical Phase
      • 8.2.5.1.3. By Therapeutic use
      • 8.2.5.1.4. By End Use
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product
      • 8.2.5.2.2. By Clinical Phase
      • 8.2.5.2.3. By Therapeutic use
      • 8.2.5.2.4. By End Use
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product
      • 8.2.5.3.2. By Clinical Phase
      • 8.2.5.3.3. By Therapeutic use
      • 8.2.5.3.4. By End Use
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product
      • 8.2.5.4.2. By Clinical Phase
      • 8.2.5.4.3. By Therapeutic use
      • 8.2.5.4.4. By End Use
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product
      • 8.2.5.5.2. By Clinical Phase
      • 8.2.5.5.3. By Therapeutic use
      • 8.2.5.5.4. By End Use

9. Middle East & Africa Clinical Trial Supplies Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Clinical Phase
    • 9.2.3. By Therapeutic use
    • 9.2.4. By End Use
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product
      • 9.2.5.1.2. By Clinical Phase
      • 9.2.5.1.3. By Therapeutic use
      • 9.2.5.1.4. By End Use
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product
      • 9.2.5.2.2. By Clinical Phase
      • 9.2.5.2.3. By Therapeutic use
      • 9.2.5.2.4. By End Use
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product
      • 9.2.5.3.2. By Clinical Phase
      • 9.2.5.3.3. By Therapeutic use
      • 9.2.5.3.4. By End Use
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product
      • 9.2.5.4.2. By Clinical Phase
      • 9.2.5.4.3. By Therapeutic use
      • 9.2.5.4.4. By End Use
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product
      • 9.2.5.5.2. By Clinical Phase
      • 9.2.5.5.3. By Therapeutic use
      • 9.2.5.5.4. By End Use
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product
      • 9.2.5.6.2. By Clinical Phase
      • 9.2.5.6.3. By Therapeutic use
      • 9.2.5.6.4. By End Use
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product
      • 9.2.5.7.2. By Clinical Phase
      • 9.2.5.7.3. By Therapeutic use
      • 9.2.5.7.4. By End Use
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product
      • 9.2.5.8.2. By Clinical Phase
      • 9.2.5.8.3. By Therapeutic use
      • 9.2.5.8.4. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Clinical Trial Supplies Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Clinical Trial Supplies Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Alamc Group
  • 12.2. Catalent, Inc.
  • 12.3. PCI Services
  • 12.4. Parexel International Corporation
  • 12.5. Sharp Packaging Services
  • 12.6. Biocair
  • 12.7. O&M Movianto
  • 12.8. KLIFO A/S
  • 12.9. Thermo Fisher Scientific, Inc.
  • 12.10. Movianto
  • 12.11. Sharp
  • 12.12. Catalent, Inc
  • 12.13. Bionical Ltd.
  • 12.14. Alium Medical Limited
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations